KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - AccuredRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Twist Bioscience (TWST) Cash & Equivalents (2018 - 2025)

Twist Bioscience (TWST) has disclosed Cash & Equivalents for 8 consecutive years, with $148.6 million as the latest value for Q4 2025.

  • Quarterly Cash & Equivalents fell 32.88% to $148.6 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $148.6 million through Dec 2025, down 32.88% year-over-year, with the annual reading at $183.0 million for FY2025, 19.12% down from the prior year.
  • Cash & Equivalents for Q4 2025 was $148.6 million at Twist Bioscience, down from $183.0 million in the prior quarter.
  • The five-year high for Cash & Equivalents was $475.3 million in Q2 2021, with the low at $148.6 million in Q4 2025.
  • Average Cash & Equivalents over 5 years is $293.0 million, with a median of $276.4 million recorded in 2023.
  • Peak annual rise in Cash & Equivalents hit 397.32% in 2021, while the deepest fall reached 45.06% in 2021.
  • Over 5 years, Cash & Equivalents stood at $191.6 million in 2021, then skyrocketed by 65.26% to $316.7 million in 2022, then fell by 15.92% to $266.3 million in 2023, then decreased by 16.85% to $221.4 million in 2024, then tumbled by 32.88% to $148.6 million in 2025.
  • According to Business Quant data, Cash & Equivalents over the past three periods came in at $148.6 million, $183.0 million, and $201.4 million for Q4 2025, Q3 2025, and Q2 2025 respectively.